Efficacy and safety of newer biologic therapies in psoriasis treatment: A systematic review and meta-analysis.
Saved in:
| Title: | Efficacy and safety of newer biologic therapies in psoriasis treatment: A systematic review and meta-analysis. |
|---|---|
| Authors: | Almutairi, Hadeel R. (AUTHOR), Althobaiti, Hanouf A. (AUTHOR), Neazy, Faris A. (AUTHOR), Alqarni, Alaa A. (AUTHOR), Alzahrani, Saleh S. (AUTHOR), Alghamdi, Sahar A. (AUTHOR), Alrezqi, Wafa Ali (AUTHOR), Aldehailan, Marwa S. (AUTHOR), Almojel, Hessah Abdulrahman (AUTHOR), Almasabi, Ghadeer Yahya (AUTHOR), Alouf, Shahad S. (AUTHOR), Alghamdi, Amjd A. (AUTHOR), Aleid, Shahd A. (AUTHOR), Alkhalifah, Azzam I. (AUTHOR) |
| Source: | Saudi Journal for Health Sciences. Sep-Dec2025, Vol. 14 Issue 3, p239-246. 8p. |
| Subjects: | Psoriasis, Biotherapy, Safety, Treatment effectiveness, Tumor necrosis factors, Interleukin-17, Critical analysis |
| Abstract: | The chronic skin disorder known as psoriasis is caused by various factors, such as genetics, environmental factors, and immune system dysfunction. It is characterized by a high number of cases of plaque psoriasis. Biologic drugs have revolutionized the treatment of this condition. Our research intends to examine the influence of biological therapies on the quality of life, comparing the effectiveness and potential risks of tumor necrosis factor alpha (TNF-α) and interleukin (IL)-17 inhibitors, assess their adverse effects, and determine their cost-effectiveness in treating psoriasis. A systematic review was carried out using Preferred Reporting Items for Systematic Reviews and Meta-analyses standards, with electronic databases searched for research on psoriasis, biologics, TNF-α, and IL-17 inhibitors. Studies published in the last 5 years were included in the study. Eligible studies encompassed randomized controlled trials, observational research, and case–control studies. Meta-analysis indicators included risk ratio (RR), standard error, random effects, and confidence intervals. A P < 0.05 was considered statistically significant, and heterogeneity was examined using random-effects regression. Despite significant variability (I 2 values: efficacy 96%, safety 94%), the meta-analysis found both interventions effective and safe. The efficacy RR of 0.69 showed substantial improvement in psoriasis control, and the safety RR of 0.54 indicated fewer side effects. Both efficacy and safety results were statistically significant (P < 0.05). Biologic therapies are effective and safe for psoriasis treatment, with a favorable risk–benefit profile. Future research should address the causes of heterogeneity and focus on improving treatment outcomes. [ABSTRACT FROM AUTHOR] |
| Copyright of Saudi Journal for Health Sciences is the property of Wolters Kluwer India Pvt Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | The chronic skin disorder known as psoriasis is caused by various factors, such as genetics, environmental factors, and immune system dysfunction. It is characterized by a high number of cases of plaque psoriasis. Biologic drugs have revolutionized the treatment of this condition. Our research intends to examine the influence of biological therapies on the quality of life, comparing the effectiveness and potential risks of tumor necrosis factor alpha (TNF-α) and interleukin (IL)-17 inhibitors, assess their adverse effects, and determine their cost-effectiveness in treating psoriasis. A systematic review was carried out using Preferred Reporting Items for Systematic Reviews and Meta-analyses standards, with electronic databases searched for research on psoriasis, biologics, TNF-α, and IL-17 inhibitors. Studies published in the last 5 years were included in the study. Eligible studies encompassed randomized controlled trials, observational research, and case–control studies. Meta-analysis indicators included risk ratio (RR), standard error, random effects, and confidence intervals. A P < 0.05 was considered statistically significant, and heterogeneity was examined using random-effects regression. Despite significant variability (I 2 values: efficacy 96%, safety 94%), the meta-analysis found both interventions effective and safe. The efficacy RR of 0.69 showed substantial improvement in psoriasis control, and the safety RR of 0.54 indicated fewer side effects. Both efficacy and safety results were statistically significant (P < 0.05). Biologic therapies are effective and safe for psoriasis treatment, with a favorable risk–benefit profile. Future research should address the causes of heterogeneity and focus on improving treatment outcomes. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 22781900 |
| DOI: | 10.4103/sjhs.sjhs_9_25 |
